Table 1 Correlation between clinicopathological features and ACTA2/IL6 mRNA co-expression in bladder cancer patients
Features | No. of patients | ACTA2/IL6 expression | p value | |
|---|---|---|---|---|
Low/Low | High/High | |||
Age (years) | ||||
< 65 | 53 | 28 (52,8%) | 25 (47,2%) | 0.6950 |
> 65 | 51 | 24 (47,1%) | 27 (52,9%) | |
Gender | ||||
Male | 85 | 48 (56,5%) | 37 (43,5%) | 0.0058** |
Female | 19 | 4 (21,1%) | 15 (78,9%) | |
Invasiveness | ||||
Superficial | 67 | 43 (64,2%) | 24 (35,8%) | 0.0001**** |
Invasive | 37 | 9 (24,3%) | 28 (75,7%) | |
Grade | ||||
Low | 75 | 43 (57,3%) | 32 (42,7%) | 0.0179* |
High | 29 | 9 (31,0%) | 20 (69,0%) | |
Lymph node metastasis | ||||
N0 | 92 | 50 (54,3%) | 42 (45,7%) | 0.0281* |
N1, N2 | 11 | 2 (18,2%) | 9 (81,8%) | |
Metastatic invasion | ||||
M0 | 99 | 50 (50,5%) | 49 (49,5%) | 1.000 |
M1 | 5 | 2 (40,0%) | 3 (60,0%) | |
Recurrence (non-invasive cancer only) | ||||
No | 36 | 26 (72,2%) | 10 (27,8%) | 0.2016 |
Yes | 31 | 17 (54,8%) | 14 (45,2%) | |
Progression | ||||
No | 63 | 34 (54,0%) | 29 (46,0%) | 0.3254 |
Yes | 41 | 18 (43,9%) | 23 (56,1%) | |